| Ytd | 55.23% | |
| 1y | 58.33% |
| Open | 2.34 | Prev Close | 2.34 | Low | 2.33 | High | 2.46 | Mkt Cap | 224.56M |
| Vol | 130.59K | Avg Vol | 380.06K | EPS | 0.38 | P/E | 6.25 | Forward P/E | -13.82 |
| Beta | 2.77 | Short Ratio | 6.42 | Inst. Own | 14.97% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 2.24 | 200-d Avg | 2.09 | 1yr Est | 4.00 |
CGEN News
Compugen has improved and now has a more forgiving runway into 2029. This should carry it through MA
Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript
Compugen NASDAQ: CGEN said its second-quarter 2026 progress included continued enrollment in its MAI
Compugen (CGEN) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus E
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.07) per share which met the analyst consensu
COM701 MAIA-ovarian trial progressing as planned with median progression-free survival data from the
HOLON, Israel, July 21, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-st
HOLON, Israel, July 20, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-s
Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer
HOLON, Israel, June 18, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-st
Compugen Ltd. (CGEN) Discusses End-to-End AI-Driven Target Discovery in Immuno-Oncology Transcript
Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer
HOLON, Israel, June 11, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-st
HOLON, Israel, June 8, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-sta
Compugen (CGEN) is maintained at a "Buy" rating, driven by advancing clinical programs and upcoming
Compugen Ltd. (CGEN) Q1 2026 Earnings Call Transcript
Compugen NASDAQ: CGEN said it remains on track to report interim progression-free survival data in t
Compugen (CGEN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimat
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.08) per share which missed the analyst conse
COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the U.S., Israel,
HOLON, Israel, May 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-sta
HOLON, Israel, May 4, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-sta
HOLON, Israel, April 9, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-st
Lake Street analyst Chad Messer initiates coverage on Compugen (NASDAQ:CGEN) with a Buy rating an
Compugen (NASDAQ: CGEN) executives used the company's fourth-quarter and full-year 2025 earnings cal
Compugen (NASDAQ:CGEN) reported quarterly earnings of $0.60 per share which beat the analyst consens
HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on Compugen (NASDAQ:CGE
Non-dilutive strategic transaction expected to extend cash runway into 2029, to advance Compugen'
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.07) per share which beat the analyst consens
Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pionee
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.08) per share which missed the analyst conse
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.08) per share which missed the analyst conse
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.07) per share which missed the analyst conse
The company announced that the United States Patent and Trademark Office (USPTO) has granted the Com
Compugen (NASDAQ:CGEN) reported quarterly earnings of $0.01 per share which missed the analyst conse
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.02) per share which beat the analyst consens